^
    Back
    Association details:
    Biomarker:No biomarker
    Cancer:Malignant Pleural Mesothelioma
    Drug:pemetrexed (Thymidylate synthase inhibitor, THF dehydrogenase inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: A1 - Approval
    Source:
    FDA
    Published date:
    01/30/2019
    Excerpt:
    ALIMTA is a folate analog metabolic inhibitor indicated...in combination with cisplatin, for the initial treatment of patients with malignant pleural mesothelioma whose disease is unresectable or who are otherwise not candidates for curative surgery.
    Secondary therapy:
    cisplatin
    Evidence Level:
    Sensitive: A1 - Approval
    Source:
    European Medicines Agency
    Published date:
    09/20/2004
    Excerpt:
    Alimta in combination with cisplatin is indicated for the treatment of chemotherapy-naïve patients with unresectable malignant pleural mesothelioma.
    Secondary therapy:
    cisplatin
    Evidence Level:
    Sensitive: A2 - Guideline
    Source:
    NICE
    Title:

    Pemetrexed for the treatment of malignant pleural mesothelioma

    Published date:
    01/23/2008
    Excerpt:
    Pemetrexed is recommended as a treatment option for malignant pleural mesothelioma only in people who have a World Health Organization (WHO) performance status of 0 or 1, who are considered to have advanced disease and for whom surgical resection is considered inappropriate.
    Evidence Level:
    Sensitive: A2 - Guideline
    New
    Source:
    NCCN
    Excerpt:
    The NCCN Panel also recommends subsequent chemotherapy options including pemetrexed (if not administered first line) (category 1), vinorelbine, or gemcitabine.
    Evidence Level:
    Sensitive: A2 - Guideline
    New
    Source:
    ESMO.org
    Title:

    Malignant pleural mesothelioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

    Excerpt:
    CONTRADICTING EVIDENCE:...Recommendations...First-line systemic therapy...Maintenance pemetrexed is not recommended in patients with non progressive MPM after first-line platinum–pemetrexed ChT [II, E].
    DOI:
    https://doi.org/10.1016/j.annonc.2021.11.005